Blood-Based Biomarkers Associated with Alzheimer's Could Detect Disease Early

Preventive Treatment Blood-Based Biomarkers Associated with Alzheimer's Could Detect Disease Early

2025-07-15 Source: Press release University of Turku 3 min Reading Time

Related Vendors

DÜPERTHAL Sicherheitstechnik GmbH & Co. KG

Bimos - eine Marke der Interstuhl Büromöbel GmbH & Co. KG

A new study has revealed that signs of the Alzheimer’s disease could be detected as early as middle age and that blood-based biomarkers associated with Alzheimer's disease can be used in the future to detect the disease early on.

A study conducted at the University of Turku in Finland found that even middle-aged individuals may have high levels of blood-based biomarkers associated with Alzheimer's disease, and the levels are higher with increasing age.(Source: Pixabay) — A study conducted at the University of Turku in Finland found that even middle-aged individuals may have high levels of blood-based biomarkers associated with Alzheimer's disease, and the levels are higher with increasing age.
(Source: Pixabay)

Turku/Finland – A Finnish population study shows that signs related to Alzheimer’s disease may already be found in the brain in middle age. In the future, blood-based biomarkers associated with Alzheimer's disease could allow earlier detection of the disease. This would allow preventive treatment to be targeted at the right individuals while the disease is still at the mild stage.

As the population ages, Alzheimer's disease and other dementing diseases are becoming more common. The disease processes leading to symptoms begin years or even decades before any decline in cognitive functions, such as memory, becomes apparent.

A study conducted at the University of Turku in Finland found that even middle-aged individuals may have high levels of blood-based biomarkers associated with Alzheimer's disease, and the levels are higher with increasing age.

A novel finding was that a high biomarker concentration in the parent, particularly mother, may be associated with higher biomarker levels in the middle-aged offspring. In addition, the researchers found that kidney disease may be linked to higher levels of biomarkers already in middle-age.

The Apoe ε4 gene, which increases the risk of Alzheimer’s disease, was associated with higher blood-based biomarker levels in older age, but not yet in middle age.

A blood sample will help diagnose Alzheimer's disease in the future

Recently, it has become possible to identify biomarkers associated with Alzheimer's disease through a blood sample. In the future, this offers a cost-effective method for identifying those at greatest risk of developing Alzheimer's disease and prioritising them for preventive treatments.

“In clinical practice, detecting beta-amyloid pathology associated with Alzheimer’s disease currently requires imaging studies or cerebrospinal fluid sampling. However, recently developed ultrasensitive measurement technologies now allow the detection of Alzheimer’s disease-related brain biomarkers from blood samples,” says Suvi Rovio, Senior Researcher at the Research Centre of Applied and Preventive Cardiovascular Medicine at the University of Turku, who led the study.

It is not yet possible to definitively diagnose Alzheimer's disease with a blood sample, as the method is still limited by the lack of well-known reference values. Additionally, it remains unclear which confounding factors influence biomarker concentrations in blood related to Alzheimer’s disease. Therefore, the interpretations of the biomarkers obtained from blood sample could lead to misdiagnosis.

“In order to reliably use blood-based biomarkers for Alzheimer’s disease diagnosis in the future, more research is needed across different population and age groups to standardize reference values," highlights Rovio.

In the study, biomarkers associated with Alzheimer's disease were measured from blood samples of middle-aged participants (aged 41–56) and their parents (aged 59–90), with a total sample size of 2,051 individuals.

“Until now, brain biomarkers associated with Alzheimer's disease have mainly been studied in older individuals. Our study provides new insights into biomarker levels and associated factors starting from middle age," says Marja Heiskanen, Senior Researcher at the Research Centre of Applied and Preventive Cardiovascular Medicine at the University of Turku.

The study is part of the national Cardiovascular Risk in Young Finns Study coordinated by the Research Centre of Applied and Preventive Cardiovascular Medicine at the University of Turku in Finland. The research results have been published in the Lancet Healthy Longevity.

Read the research article:Factors related to blood-based biomarkers for neurodegenerative diseases and their intergenerational associations in the Young Finns Study: a cohort study

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Date: 08.12.2025

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.

(ID:50483153)